NCT03498612

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of Washington · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial studies how well pembrolizumab works in treating patients with B-cell non-Hodgkin lymphoproliferative diseases that have not been treated. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Detailed description

OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then up to 5 years.

Conditions

• Follicular Lymphoma
• Indolent B-Cell Non-Hodgkin Lymphoma
• Marginal Zone Lymphoma

Interventions

Type	Name	Description
OTHER	Laboratory Biomarker Analysis	Correlative studies
BIOLOGICAL	Pembrolizumab	Given IV

Timeline

• Start date: 2018-07-09
• Primary completion: 2021-06-09
• Completion: 2024-08-29
• First posted: 2018-04-13
• Last updated: 2025-11-12
• Results posted: 2022-12-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study